Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $31.81, for a total value of $222,670.00. Following the transaction, the insider owned 1,518 shares of the company’s stock, valued at approximately $48,287.58. This represents a 82.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Joana Goncalves also recently made the following trade(s):

• On Friday, December 19th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $30.61, for a total transaction of $214,270.00.

Oruka Therapeutics Stock Up 2.8%

ORKA stock traded up $0.90 during mid-day trading on Friday, hitting $33.40. 715,063 shares of the company were exchanged, compared to its average volume of 502,813. Oruka Therapeutics, Inc. has a 12-month low of $5.49 and a 12-month high of $33.85. The firm has a market capitalization of $1.62 billion, a P/E ratio of -17.58 and a beta of -0.39. The business has a fifty day simple moving average of $29.49 and a 200-day simple moving average of $21.89.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. Research analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Wall Street Analyst Weigh In

ORKA has been the topic of several research reports. Barclays began coverage on shares of Oruka Therapeutics in a research report on Monday, October 13th. They set an “overweight” rating and a $48.00 price target on the stock. Wedbush increased their target price on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday. UBS Group initiated coverage on shares of Oruka Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target for the company. HC Wainwright reduced their price objective on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.67.

Institutional Trading of Oruka Therapeutics

A number of large investors have recently made changes to their positions in ORKA. Synergy Asset Management LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at approximately $13,911,000. SG Americas Securities LLC acquired a new stake in shares of Oruka Therapeutics during the fourth quarter worth about $251,000. Woodline Partners LP grew its holdings in shares of Oruka Therapeutics by 46.9% during the third quarter. Woodline Partners LP now owns 574,330 shares of the company’s stock worth $11,044,000 after buying an additional 183,426 shares during the last quarter. Polar Capital Holdings Plc increased its position in Oruka Therapeutics by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,032,307 shares of the company’s stock valued at $19,851,000 after acquiring an additional 57,307 shares during the period. Finally, Palo Alto Investors LP acquired a new position in Oruka Therapeutics in the 3rd quarter valued at about $1,154,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.